Submissions for variant NM_002693.3(POLG):c.3286C>T (p.Arg1096Cys)

gnomAD frequency: 0.00003  dbSNP: rs201732356

Total submissions: 15

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel, ClinGen	RCV001753588	SCV001994832	likely pathogenic	Mitochondrial disease	2021-05-23	reviewed by expert panel	curation	The c.3286 C>T (p.Arg1096Cys) variant in POLG is seen at an allele frequency of 0.00001 in gnomAd and 0.00002 in ExAC with no homozygotes (PM2). This variant has a Revel score of 0.837 (PP3). There are 7 cases in the literature reported with an Alpers phenotype in individuals who are homozygous for the c.3286 C>T (p.Arg1096Cys) (PM3_strong; PMID:21305355; PMID:21880868; PMID:18546365). There are also 6 cases reported with other pathogenic variants with phasing unknown 2 siblings reported compound heterozygous with Thr914Pro, another reported with Trp748Ser, another cases with Leu591Phe, another case with Ala467Thr, and another case with Gly848Ser. Each case was reported with POLG related disease with Alpers, liver related disease, and other neurological phenotypes (PM3_strong; PMID:18487244; PMID:30021052; PMID:24265579; PMID:27111573; PMID:21880868). In summary, this variant meets criteria to be classified as likely pathogenic for mitochondrial disease inherited in an autosomal recessive manner. ntDNA ACMG/AMP criteria for POLG applied: PM2, PP3, PM3_strong
GeneDx	RCV000188613	SCV000242236	pathogenic	not provided	2022-01-11	criteria provided, single submitter	clinical testing	Reported previously in multiple patients with Alpers syndrome, a clinical presentation suggestive of POLG deficiency, or progressive external ophthalmoplegia (arPEO) and peripheral neuropathy, who were either homozygous for the R1096C variant (Mohamed et al., 2011; Wong et al, 2008; Tang et al., 2011; Ashley et al. 2008) or compound heterozygous for the R1096C variant and another pathogenic variant (Tang et al., 2011; Ashley et al., 2008; Lax et al., 2012); Functional studies have demonstrated that the R1096C variant results in a decreased catalytic efficiency in incorporating correct dNTP into DNA (Sohl et al., 2013); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28471437, 29655203, 22189570, 24265579, 21305355, 12707443, 25129007, 23545419, 19578034, 25786813, 20164463, 21880868, 18487244, 23208208, 21138766, 29474836, 30167885, 31521625, 31130284)
Eurofins Ntd Llc (ga)	RCV000188613	SCV000706348	pathogenic	not provided	2017-02-08	criteria provided, single submitter	clinical testing
Wong Mito Lab, Molecular and Human Genetics, Baylor College of Medicine	RCV000758420	SCV000887123	pathogenic	Progressive sclerosing poliodystrophy	2018-10-01	criteria provided, single submitter	clinical testing	The NM_002693.2:c.3286C>T (NP_002684.1:p.Arg1096Cys) [GRCH38: NC_000015.10:g.89318737G>A] variant in POLG gene is interpretated to be a Pathogenic based on ACMG guidelines (PMID: 25741868). This variant has been reported in PMID:12707443 ; 21305355 . This variant meets the following evidence codes reported in the ACMG-guideline. PS1:This variation causes same amino-acid change as an established pathogenic variant. PS3:Well established functional studies show a deleterious effect on POLG. PM2:This variant is absent in key population databases. PM3:Detected in trans with a pathogenic variant for Mitochondrial DNA depletion syndrome 4A (Alpers type) which is a recessive disorder. PP1:This variant is co-segregated with Mitochondrial DNA depletion syndrome 4A (Alpers type) in multiple affected family members. PP4:Patient's phenotype or family history is highly specific for POLG. Based on the evidence criteria codes applied, the variant is suggested to be Pathogenic.
Department Of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University	RCV000758420	SCV000891542	likely pathogenic	Progressive sclerosing poliodystrophy	2017-12-30	criteria provided, single submitter	curation
Fulgent Genetics, Fulgent Genetics	RCV000762952	SCV000893384	likely pathogenic	Progressive sclerosing poliodystrophy; Mitochondrial DNA depletion syndrome 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1; Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; Mitochondrial DNA depletion syndrome 4b	2018-10-31	criteria provided, single submitter	clinical testing
Invitae	RCV000758420	SCV001391869	pathogenic	Progressive sclerosing poliodystrophy	2024-01-26	criteria provided, single submitter	clinical testing	This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1096 of the POLG protein (p.Arg1096Cys). This variant is present in population databases (rs201732356, gnomAD 0.004%). This missense change has been observed in individuals with autosomal recessive POLG-related disease (PMID: 21305355, 21880868, 22189570, 24265579, 28471437, 30167885). This variant has been reported in individual(s) with autosomal dominant progressive external ophthalmoplegia (PMID: 12707443); however, the role of the variant in this condition is currently unclear. ClinVar contains an entry for this variant (Variation ID: 206556). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt POLG protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects POLG function (PMID: 20185557, 23208208). This variant disrupts the p.Arg1096 amino acid residue in POLG. Other variant(s) that disrupt this residue have been observed in individuals with POLG-related conditions (PMID: 16621917, 19752458), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics	RCV000758420	SCV001524399	pathogenic	Progressive sclerosing poliodystrophy	2020-07-09	criteria provided, single submitter	clinical testing	This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
Kariminejad - Najmabadi Pathology & Genetics Center	RCV001814095	SCV001755652	pathogenic	Abnormality of the nervous system	2021-07-10	criteria provided, single submitter	clinical testing
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen	RCV000188613	SCV001762045	pathogenic	not provided	2021-06-17	criteria provided, single submitter	clinical testing
3billion	RCV000758420	SCV002572950	pathogenic	Progressive sclerosing poliodystrophy	2022-09-01	criteria provided, single submitter	clinical testing	The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.001%). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.84; 3Cnet: 0.89). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000206556). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals (PMID: 18487244 , 18546365 , 21305355 , 21880868 , 24265579 , 27111573 , 30021052). Different missense changes at the same codon (p.Arg1096Gly, p.Arg1096His, p.Arg1096Leu) have been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000206555 , VCV000206557 , VCV000206559). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.
Al Jalila Children's Genomics Center, Al Jalila Childrens Speciality Hospital	RCV000188613	SCV002818138	pathogenic	not provided	2022-12-17	criteria provided, single submitter	clinical testing
PreventionGenetics, part of Exact Sciences	RCV003985757	SCV004742566	pathogenic	POLG-related disorder	2023-11-01	criteria provided, single submitter	clinical testing	The POLG c.3286C>T variant is predicted to result in the amino acid substitution p.Arg1096Cys. This variant has been reported to be causative for autosomal recessive POLG-associated disorders such as sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO), progressive external ophthalmoplegia (PEO) and sensory neuropathy, and Alpers’ Syndrome (Kurt et al. 2012. PMID: 24265579; Lax et al. 2012. PMID: 22189570; Ashley et al. 2008. PMID: 18487244; Hikmat et al. 2017. PubMed ID: 28471437). At least one heterozygous carrier of this particular variant presented with sporadic PEO (Agostino et al. 2003. PMID: 12707443). This variant is reported in 0.0040% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-89861968-G-A). This variant is interpreted as pathogenic.
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center	RCV003984830	SCV004801145	likely pathogenic	Mitochondrial DNA depletion syndrome 4b	2024-03-14	criteria provided, single submitter	research
Center of Excellence in Genomics and Precision Dentistry, Faculty of Dentistry, Chulalongkorn University	RCV001263172	SCV001245409	pathogenic	Childhood myocerebrohepatopathy spectrum		no assertion criteria provided	research	The p.Arg1096Cys variant in POLG gene has been previously reported many times with autosomal recessive inheritance pattern. Homozygous mutation of this variant was reported in a Saudi child with Alpers-Huttenlocher syndrome (AHS) (Kentab, 2019). Other reports could be accessed in The POLG Pathogenicity Prediction Server (http://polg.bmb.msu.edu).